Overview

Mild, Moderate and Severe Renal Impairment Study

Status:
Completed

Trial end date:
2016-05-13

Target enrollment:

Participant gender:

Summary

This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Ardea Biosciences, Inc.

Treatments:

Verinurad